Navigation Links
Dermal in Biological Technology

Dr. Daniel Ronel Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler

... patients who are looking for a longer lasting dermal filler. Dr. Ronel has been an avid Artefill user ... is injected with Artefill similar to other dermal fillers with the key difference being its lasting ... feeling results. This is different from temporary dermal fillers that are made of different kinds of ...

Photos: FDA Approves 12-Month Labeling Update for EVOLENCE(R) Collagen-Based Facial Filler

... 12 months for EVOLENCE(R), a collagen-based dermal filler for the correction of moderate to deep ... EVOLENCE(R) is the first and only collagen dermal filler recognized to provide results through 12 ... initial treatment*. EVOLENCE(R), the first dermal filler entry for Ortho Dermatologics, was ...

BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008

... update on its product pipeline: -- RADIESSE(R) dermal Filler Next-Generation Products: The Company has ... indications of its patent protected RADIESSE dermal filler technology. The first new commercial ... efforts is expected to be a form of RADIESSE dermal filler with Lidocaine which may improve ...

Radiesse(R) Dermal Filler Featured Prominently in Journal of Dermatologic Surgery Special Issue on Fillers

... recent papers demonstrate safety with Radiesse(R) dermal filler in 1000 patients over 4 years, evidence ... in various prestigious journals, Radiesse dermal filler is one of the most rigorously studied ... the safety and effectiveness of Radiesse dermal filler in treatment of nasolabial folds, ...

DermAvance Pharmaceuticals Announces Investment by Ben Franklin Technology Partners of Southeastern Pennsylvania

... a patent protected combination, second generation dermal filler. dermal fillers are used to reverse changes associated ... with the baby boomers coming of age, and the US dermal filler market is projected to reach $1 billion by ...

NeurogesX' Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union

... products for pain. Qutenza is a high-concentration capsaicin dermal patch designed to provide rapid, localized and sustained relief from ... late stage product portfolio is led by its product candidate Qutenza, a dermal patch designed to manage pain associated with peripheral neuropathic pain ...

Palomar and Q-MED AB Terminate International Distribution Agreement

... Q-MED's efforts are being concentrated on their own product line of dermal fillers. Both Palomar and Q-MED agreed that Palomar will be better served ... present challenging market conditions, Q-Med is focusing on its leading dermal filler product line, Restylane(R) as well as on the on-going launch of ...

Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes

... (PG) receptors. PG receptors are present in hair, particularly in the dermal papilla and outer root sheath. Although the precise mechanism of action ... portfolio, including BOTOX(R) Cosmetic; hyaluronic acid and collagen-based dermal fillers; and physician-dispensed skin care products. Allergan Medical ...

NeurogesX to Report Third Quarter 2008 Financial Results

... late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain ... a liquid, NGX-1998 is expected to be suitable for areas of the skin where dermal patches may be difficult or impractical to apply, such as the hairline. ...

NeurogesX Reports Second Quarter 2008 Results

... late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain ... a liquid, NGX-1998 is expected to be suitable for areas of the skin where dermal patches may be difficult or impractical to apply, such as the hairline. ...

NeurogesX Reports First Quarter 2008 Results

... development expected in second quarter of 2008 - NDA submission for dermal patch, NGX-4010, in PHN expected in second half ... late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain ...

Palomar and Q-MED AB Enter Into International Distribution Agreement

... the producer of Restylane, one of the most popular and widely distributed dermal fillers in the world, with over 9 million treatments provided so far. ... effects of Palomar's light-based systems with Q- MED's leading range of dermal fillers and injectable implants. Both companies are focused on developing ...

Transport Pharmaceuticals Receives Coveted Frost & Sullivan Technology Innovation Award

... of creating a system which is poised to revolutionize the field of dermal drug delivery." The Challenges and Promise of Transdermal Delivery The ... a high dose of potent drug rapidly and painlessly reaches the affected dermal tissue, while the patient avoids the potential toxicity and adverse ...

Echo Therapeutics Reports Third Quarter 2007 Results

... of well-established, FDA-approved products using Echo's AzoneTS dermal penetration enhancement technology in concert with a 505(b)(2) ... well-established, FDA-approved products using its proprietary AzoneTS(TM) dermal penetration technology. Echo has submitted a New Drug Application (NDA) to ...

NeurogesX Reports Second Quarter 2009 Results

... (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza(TM), a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is currently approved in the European Union for the ...

NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application

... (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza(TM), a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is currently approved in the European Union for the ...

NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results

... (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza((TM)), a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is currently approved in the European Union for the ...

Seasoned Dermatologist Nissan Pilest of Irvine, CA, Joins SDS Clinical Trials as Clinical Investigator for Dermatology Division

... in the advanced injection techniques of Allergan products Juvederm and Botox, is on the Medical Education Faculty for Bioform's Radiesse long term dermal filler and also is a physician trainer for Restylane and Perlane and the new neurotoxin Dysport. He is the medical director of Total Dermatology, ...

High-Tech 'Smart' Face Mask Helps Hong Kong Families Combat Swine Flu

... terms of all the major routes of exposure, oral, dermal and inhalation, it showed no harmful effects on humans. The BioMask(TM) has been tested for dermal biocompatibility following internationally recognized standards set out in ISO10933: Biological Evaluation of Medical Devices. Tests were conducted ...

NeurogesX Added to Russell 3000 Index

... polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is currently approved in the European Union for the ...

Australia: Face Mask That Kills Swine Flu Readied for Australian Pandemic Fight

... tested in terms of all the major routes of exposure, dermal and inhalation, it showed no harmful effects on humans. The BioMask has been tested for dermal biocompatibility following internationally recognized standards set out in ISO10933: Biological Evaluation of Medical Devices. Tests were conducted ...

NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)

... polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is currently approved in the European Union for the ...

Orange County Laser Surgeon Nissan Pilest Tapped as Keynote Speaker at Fraxel & Thermage User Forum Held at Beckman Laser Institute

... Total Dermatology, is located in Irvine, Ca. His clinic is a popular choice for all cosmetic dermatology applications, with a special focus on dermal fillers, Botox and lasers. Consultations are available by calling (949) 727 3800 or contacting the practice via their website ...

NeurogesX to Present at Needham Life Sciences Conference

... (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza(TM), a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is currently approved in the European Union for the ...

NeurogesX Receives European Commission Approval for Qutenza(TM)

... polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is currently approved in the European Union for the ...

NeurogesX Reports First Quarter 2009 Results

... polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late-stage product portfolio is led by its product candidate QutenzaTM, a dermal high-concentration capsaicin patch designed to manage pain associated with peripheral neuropathic pain conditions. NeurogesX submitted a new drug ...

NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results

... polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. NeurogesX submitted a new drug application (NDA) for Qutenza to ...

NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting

... peripheral neuropathic pain, including PHN, HIV-DSP and PDN. NeurogesX' late stage product portfolio is led by its product candidate Qutenza, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the Company believes offers significant advantages over ...

Histogen Aesthetics Launches ReGenica Rejuvenation System

... Rejuvenation System for anti-aging and post-resurfacing. Histogen Aesthetics utilizes a proprietary manufacturing process in which newborn dermal fibroblast cells are grown on beads in controlled bioreactors that maintain an embryonic-like environment, including low oxygen and low gravity ...

NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update

... polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the Company believes offers significant advantages over ...

NeurogesX to Present at 11th Annual BIO CEO & Investor Conference

... polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late-stage product portfolio is led by its product candidate QutenzaTM, a dermal high concentration capsaicin patch designed to manage pain associated with peripheral neuropathic pain conditions, that the Company believes offers ...

Irvine Dermatologist Begins In-office Clinical Studies -- Nissan Pilest, MD Combines Multi-Use Botox in Laser Resurfacing Clinical Studies

... medical use in migraine, back pain and TML Used along with fillers, Dr. Pilest finds that Botox also tends to typically prolong the effects of the dermal fillers by restricting muscle activity that drives filler component breakdown. Dr. Pilest enthuses, "For a fast, simple and practically ...

Dr. Gail Naughton Speaks on Histogen's Business Plan and the Rise of Bioaesthetic Medicine during Commercial Translation of Regenerative Medicine

... human extracellular matrix which is grown in a simulated embryonic environment, is currently being evaluated for a variety of applications, from dermal fillers to implant coatings," said Dr. Robert Kellar, VP of Research and Development at Histogen. "Intriguing preliminary results from ...

Transdermal Diclofenac enters Phase 1 Clinical Trial in Humans

... Australia, the Principal Investigator is Professor Allan Evans. The trial is an open label, single centre bioavailability and penetration trial of dermal and systemic pharmacokinetics in 12 healthy adult volunteers, incorporating secondary endpoints of safety and tolerability. The Company expects to ...

NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference

... polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the Company believes offers significant advantages over ...

NeurogesX Reports Third Quarter 2008 Results

... polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the Company believes offers significant advantages over ...

NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)

... polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the Company believes offers significant advantages over ...

Histogen Aesthetics is Created to Address Growing Medical Aesthetics Market

... San Diego/Phoenix (PRWEB) October 20, 2008 -- Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn dermal fibroblasts, today announced the creation of Histogen Aesthetics LLC, a venture developing products for the growing medical aesthetic industries ...

NeurogesX Responds to EMEA's Day 120 Questions

... polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the Company believes offers significant advantages over ...

MIGENIX Reports First Quarter Fiscal 2009 Financial Results

... a NDA in 2011, Cutanea expects: - in the first quarter of calendar 2009, to initiate chronic toxicology studies, specifically the required dermal carcinogenicity study, which Cutanea expects will be the rate limiting activity for submission of the NDA; and - in the second half of ...
Other Contents
(Date:9/1/2014)... and decisions of the Nomenclature Section of the XVIII ... July 2011. This meeting is held every six years ... the rules for naming algae, fungi and plants get ... naming the organisms they study. This is the primary ... for algae, fungi, and plants, which was published in ...
(Date:8/31/2014)... not busy attacking us, germs go after each other. ... disaster for the infected microbes: Sometimes viruses actually carry ... expand its diet or better attack its own hosts. ... immune system would robotically destroy anything it recognized as ... have now revealed that one variety of the bacterial ...
(Date:8/29/2014)... Researchers at UC Davis have made some surprising ... infection. Studying simian immunodeficiency virus (SIV), the team ... Paneth cells are early responders to viral invasion ... producing a cytokine called interleukin-1 beta (IL-1β). ... IL-1β causes breakdown of the gut epithelium that ...
Breaking Biology News(10 mins):Week-long meeting on naming algae, fungi, and plants recorded for posterity 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 3The early cost of HIV 2
(Date:9/1/2014)... Wellesley, Mass., (PRWEB) September 01, 2014 ... report, BLOOD-BRAIN BARRIER TECHNOLOGIES AND GLOBAL MARKETS ... reached $21.8 million in 2013 and is expected to ... further grow to $471.5 million by 2019, which is ... 2014 through 2019. The receptor-mediated transport (RMT) segment is ...
(Date:9/1/2014)... 2014 Parties involved in federally-filed Tylenol ... litigation’s status conference in September, where issues related to ... the Eastern District of Pennsylvania, Bernstein Liebhard LLP reports. ... posted on the Court’s website, the meeting is scheduled ... a.m. This is the latest of several Tylenol conferences ...
(Date:9/1/2014)... Ontraport , one of the latest ... to automate the small intricacies of managing an online ... prompting an investigative review. , “As a new ... all of the small details involved with running a ... “That’s why Ontraport has become so popular in this ...
(Date:9/1/2014)... AttorneyOne.com, a recognized authority on law, update ... the FDA on DePuy Synthes Craniomaxillofacial Distraction System ... 28, that specific lots of DePuy Synthes Craniomaxillofacial Distraction ... device may reverse directions after surgery. According to ... is an implant used to lengthen and/or stabilize the ...
(Date:9/1/2014)... 01, 2014 Beginning Tuesday, September 2nd, ... medical professionals and 10,000 consumers for the annual gathering ... gathering of the nation’s top medical professionals who specializes ... conditions. The week-long event contains more than 120 hours ... available in the pain management field. , MarijuanaDoctors.com is ...
Breaking Medicine News(10 mins):Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Ontraport: Review Exposes Automated Platform for Online Marketing Management 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 3Health News:Medical Marijuana Doctor Company Set to Present at Las Vegas Pain Week 2
Other TagsOther Tags